OncoDNA completes its portfolio with advanced genomic services and NGS data analysis tools
FOLLOWING THE ACQUISITION OF INTEGRAGEN, ONCODNA HAS CREATED A UNIQUE, INTEGRATED PORTFOLIO OF SMART AND PERSONALIZED SOLUTIONS TO HELP CLINICIANS, ACADEMIC RESEARCHERS AND BIOPHARMA COMPANIES ACROSS THE WORLD TO OUTSMART THE MOLECULAR COMPLEXITY OF CANCER AND GENETIC DISEASES.
Since the successful takeover of IntegraGen in November 2020, OncoDNA has been working hand in hand with its new partner towards the consolidation of their respective teams and services. The acquisition brought together two companies of complementary expertise. While OncoDNA biomarker tests are recognized for guiding and monitoring the treatment of advanced cancer patients, IntegraGen is a leading player in DNA sequencing services with specialized expertise in exome and complete genome analyses. The company runs one of the largest NGS labs in France and operates for research institutes of excellence. Not to mention that it has also developed a variety of software for genomic data interpretation that are already commercialized in Europe and the USA.
With IntegraGen on board, OncoDNA is leveraging the power of next generation sequencing to bring precision medicine to a new level. Comprehensive genomic analysis has become increasingly important for diagnostic and research of complex genetic diseases such as cancer. By combining their forces, OncoDNA group has the potential to become the European leader in this emerging field. It took on the challenge of offering the best of genomic analyses and software with the objective of facilitating the translation of therapeutic innovation to the clinics and having a greater impact on patient care.
From now on, OncoDNA group will offer a unique, highly integrated portfolio that addresses the needs of the whole value chain – from translational research and drug development to patient treatment and monitoring. Through a comprehensive range of genomic services, biomarker tests, data interpretation and clinical decision support tools, it will provide academic researchers, biopharma companies and clinicians the molecular insights they need for their research projects, clinical trials and clinical decision-making.
Exome, whole genome and custom gene panel sequencing services for cancer and rare diseases.
RNA sequencing services to precisely measure transcriptome expression in tissue samples or liquid biopsies.
Cost-effective and high-throughput services to analyze genome-wide methylation profiles.
Cost-effective and flexible services to interrogate 10’s to millions SNP markers in a timely manner.